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Immunotherapy efficacy relies on the crosstalk within the tumor microenvironment between cancer and 
dendritic cells (DCs) resulting in the induction of a potent and effective antitumor response. DCs have 
the specific role of recognizing cancer cells, taking up tumor antigens (Ags) and then migrating to lymph 
nodes for Ag (cross)-presentation to naïve T cells. Interferon-α-conditioned DCs (IFN-DCs) exhibit 
marked phagocytic activity and the special ability of inducing Ag-specific T-cell response. Here, we have 
developed a novel microfluidic platform recreating tightly interconnected cancer and immune systems 
with specific 3D environmental properties, for tracking human DC behaviour toward tumor cells. By 
combining our microfluidic platform with advanced microscopy and a revised cell tracking analysis 
algorithm, it was possible to evaluate the guided efficient motion of IFN-DCs toward drug-treated 
cancer cells and the succeeding phagocytosis events. Overall, this platform allowed the dissection of 
IFN-DC-cancer cell interactions within 3D tumor spaces, with the discovery of major underlying factors 
such as CXCR4 involvement and underscored its potential as an innovative tool to assess the efficacy of 
immunotherapeutic approaches.
Immunotherapy relies on the use of therapeutic agents that are able to potentiate immune effector mechanisms 
also inside the tumor microenvironment (TME)1. In this context, the adjuvant capacity of dendritic cells (DCs) 
is crucial in determining the success of these treatments, especially in case of poorly immunogenic tumors2. DCs 
have the capability to scan the microenvironment and to capture and present antigens (Ag) to lymphocytes to 
generate an antitumor immune response3. Since the balance between stimulatory and suppressive signals within 
the TME determines DC functions, the prevalence of immunosuppressive inflammation hampers the antitumor 
activities of these cells and the development of an efficient antitumor immunity2. Conversely, tumor treatment 
with agents that favour the release of immunogenic signals by dying cancer cells promotes the adjuvant capa-
bility of DCs to induce antitumor responses4–6. Recent studies have demonstrated that epigenetic therapies are 
able to determine tumor lysis and re-establish endogenous immune recognition thus enhancing the antitumor 
immune response. In addition, epigenetic drugs and immunotherapy have been proposed as a particularly prom-
ising combination to combat cancer7. Along this line, we have recently reported that the combination of IFN-α 
(I) and epigenetic drugs, such as the DNA methyltransferase inhibitor (DNMTi) 5-azacitidine and the histone 
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deacetylase inhibitor (HDACi) romidepsin (R) represents an efficacious antitumor treatment with a high poten-
tial to induce immunogenic apoptosis of colorectal cancer (CRC) cells8. Upon phagocytosis of dying cancer cells, 
DCs fulfil their primary role by processing and presenting tumor Ags to CD4+ T helper cells, while some subsets 
of DCs possess the capability to cross-present tumor Ags to CD8+ T cells, and thus stimulate the effector cells 
of the antitumor response9. These peculiar DC functions evoking antitumor immunity have been exploited in 
several DC-based therapeutic approaches. In our laboratory, we developed IFN-α-conditioned DCs (IFN-DCs) 
as promising candidates for therapeutic cancer vaccines10. These cells possess superior properties in Ag uptake 
and induction of both CD4+ T helper lymphocytes and CD8+ cytotoxic T cells and resemble naturally occurring 
DCs11–13. It is important to note that the superior functional activities of IFN-DCs, as well as the rapid acquisi-
tion of their potent migratory ability, may also depend on the expression of chemokine receptors14. Data from a 
pilot clinical study indicate that in patients with advanced melanoma, intratumoral injection of IFN-DCs after 
dacarbazine treatment activates antitumor immunity confirming the high capability of these cells to fulfil their 
functions upon Ag release in situ15.
Microfluidic models represent a new frontier for studying the complex interactions occurring within organ 
microenvironments in both physiologic and pathologic conditions16, 17. The recent advances in both cell biology 
and microengineering have allowed the development of the innovative organ-on-chip approach, which is able 
to recapitulate in vivo biological microenvironments suitable for studying complex functions, such as cell-cell 
interactions and dynamic drug stimuli18, 19. This enormous potential relies first on the recreation of complex 
3D spaces characterized by both physical and biochemical cues closely mimicking the in vivo microenviron-
ments20. Importantly, microfluidic platforms are able to reproduce cell confinement, a parameter imposed on cell 
movement in the interstitial space of tissues, which is totally absent in 2D assays. This confinement is essential 
for studying the behaviour of motile cells such as immune and cancer cells21. The coordinated integration of a 
microfluidic assay, advanced microscopy and computational modelling enables the observation of single events as 
part of the complex biological processes ultimately leading to define the physiopathological responses22, 23. These 
breakthrough innovations have allowed the study of cancer-immune interactions as well as immunotherapeutic 
treatments using microfluidic platforms24. In oncology, microfluidic models have been widely used to study the 
metastatic potential of cancer cells25, 26. In the past few years, our group exploited the microfluidic approach to 
investigate in real time the interactions between immune and cancer cells occurring during an IRF-8-deficient 
antitumor immune response27, 28. This approach provides a new method to investigate these events also under 
therapeutic treatments29. However, one major challenge is the proper reconstruction of tumor and immune sys-
tems, two different microenvironments closely interconnected.
Here, we reconstituted 3D spaces mimicking cancer and immune systems suitable to investigate the physical- 
and biochemical-driven interactions among these cell components. Specifically, we monitored the behaviour 
of IFN-DCs toward CRC cells, untreated or exposed to the innovative antitumor combined treatment with R 
and I (RI). We found that IFN-DCs moved through 3D immune and tumor spaces with a driven trajectory 
toward RI-treated cancer cells rather than untreated (NT) counterpart. Noteworthy, during dynamic migration, 
largely guided by the CXCR4/CCL12 axis, IFN-DCs were found to modify their motion in order to interact with 
drug-treated cancer cells and then to take up tumor Ags.
Results
A 3D microfluidic platform enables the evaluation of dynamic IFN-DC migration toward SW620 
cancer cells exposed to combined treatment with IFN-α and romidepsin. The success of IFN-
DC-based immunotherapy relies on the ability of these cells to accomplish Ag uptake by phagocytosis of dying 
cells in the TME and then to migrate to lymph nodes where they induce T cell-mediated antitumor responses15, 30. 
To investigate the interactions between IFN-DCs and SW620 CRC cells, we built a microfluidic platform suitable 
to recreate interconnected 3D spaces. To this end, we first generated primary IFN-DCs by culturing peripheral 
monocytes from healthy donors for 3 days with I and GM-CSF. In addition to the high expression of the co-stim-
ulatory molecules CD80 and CD86, IFN-DCs were found to display the plasmacytoid CD123 marker as well 
as the type 2 myeloid DC marker BDCA3, which are involved in the cross-presentation of Ags derived from 
pathogens and dead cells31, 32 (Fig. 1a). Based on our previous data showing the ability of RI to promote DC rec-
ognition of cancer cells8, we then evaluated the phagocytic capacity of IFN-DCs toward SW620 cells pre-exposed 
to RI (RI SW620) for 48 h. We found that RI treatment markedly induced both early and late apoptosis in SW620 
cells that in turn were phagocytosed at a higher rate by the IFN-DCs as compared to untreated cancer cells (NT 
SW620) (Fig. 1b,c). Therefore, in order to study the behaviour of IFN-DCs toward NT and RI SW620 we devised 
a novel strategy combining the design of a hydrogel-based microchannel platform with advanced microscopy as 
well as an unsupervised image processing algorithm. This approach allowed us to perform, on a single-cell basis, 
real time monitoring and analysis of DC migration as well as to evaluate the interactions occurring between 
IFN-DCs and SW620 cells. Figure 2a shows the microfluidic platform, containing a central immune culture 
compartment (immune-chamber) where floating IFN-DCs were uniformly distributed and showed non-adhe-
sive motion, resembling the peripheral immune system. Two-side narrow chambers (tumor-chambers) were 
designed to establish 3D tumor microenvironments by embedding with a type I collagen matrix, where NT or 
drug-treated SW620 cells were seeded through two loading reservoirs, thus establishing 3D-NT and 3D-RI tumor 
spaces, respectively. On the basis of the already reported unique suitability of type I collagen for reproducing DC 
behaviour in the extracellular matrix33, it was used to build tumor-chambers re-creating proper biochemical and 
biophysical factors guiding DC migration and function. Each tumor-chamber, flanked on the external side by a 
parallel wide channel deputed to perfuse complete medium to the cultures, was connected to the immune-cham-
ber via a set of short and narrow capillary migration channels (connecting-channels) (Fig. 2a,b, Supplementary 
Fig. 1). This geometry allowed to analyse DCs that move under confinement performing distinct processes such 
as migration, phagocytosis and cell-cell interactions, as it occurs in vivo during extravasation into peripheral 
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tissues34, 35. For this purpose, two experimental configurations were used: (i) a no-competition condition, where 
the left tumor-chambers of two distinct platforms were functionalized with collagen without tumor cells (matrix) 
while collagen-embedded NT or RI-treated SW620 cells were cultured in the right tumor-chambers (Fig. 2c, left 
panel); (ii) a competition condition, where collagen-embedded NT SW620 and RI-treated SW620 cells (hereafter 
NT and RI) were placed in the left and in the right tumor-chambers, respectively, of the same platform (Fig. 2c, 
right panel). Such design provided the opportunity to re-create a microsystem characterized by interconnected 
tumor and immune compartments, yet retaining specific environmental properties. This model allowed to mon-
itor the motility of IFN-DCs (migrating IFN-DCs) through the immune-chamber, connecting-channels, and 
tumor-chamber, in the presence of either non-competitive signals (no-competition) or biochemical stimuli (com-
petition) and also to evaluate the overall recruitment of IFN-DCs into the 3D tumor space (infiltrated IFN-DCs) 
and their interactions with SW620 cells (Fig. 2d).
Figure 1. IFN-DCs efficiently phagocytose RI-treated SW620 cells. (a) Human monocyte-derived DCs 
generated in the presence of both IFN-α2b and GM-CSF were analysed by flow cytometry for the expression 
of maturation and differentiation markers. Percentages of positive cells (filled histograms) are shown; empty 
histograms represent isotype controls. Data are representative of three independent experiments. (b) Analysis 
of apoptosis of SW620 cells induced by 48 h-treatment with the combination of romidepsin and IFN-α2b 
(RI), as compared to untreated (NT) cancer cells. In the flow plots, early apoptotic cells (Annexin V+/PI−), late 
apoptotic cells (Annexin V+/PI+), necrotic cells (Annexin V−/PI+) and vital cells (Annexin V−/PI−) can be 
distinguished. One representative experiment out of four independent experiments is shown (left panel). In 
the right panel, percentages ± s.d. of AnnV+/PI− and AnnV+/PI+ cells are shown (N = 4). (c) Flow cytometry 
analysis of phagocytosis of NT or RI-treated PKH26-labeled SW620 cells by IFN-DCs after a 4 h co-culture. 
IFN-DCs were stained with anti-CD11c mAb. One representative experiment (left panel) and the mean 
percentage ± s.d. of phagocytosed cells (right panel) are shown (N = 3).
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Figure 2. Design of the microfluidic device reconstructing the 3D immune-cancer spaces to track DC-
cancer cells dialogue. (a) Schematic model of the 3D microfluidic device used for real time monitoring of 
DC migration toward cancer cells and their interactions. The device is composed of a 1.2 mm-wide central 
immune-chamber, with rounded loading reservoirs at both ends for DC loading, connected through a network 
of narrow microgrooves (connecting-channels) (10 × 12 × 200 µm, H × W × L) to two side tumor-chambers 
(150 × 500 × 1000 µm) end-closed with rounded loading reservoirs and designed to recreate 3D tumor spaces. 
Two external medium chambers ensure the optimal gas and nutrient exchange to the cell cultures. An enlarged 
3D section of the device is shown. The boxed area represents a magnification of the connecting-channels. 
(b) Fluorescence image of the immune-tumor area of the device analysed in microfluidic experiments (left 
panel) showing the immune-chamber filled with PKH67 green-stained DCs, the connecting-channels and the 
tumor-chamber loaded with type I collagen embedded-PKH26 red-stained cancer cells. Images were acquired 
with an inverted Olympus IX73 microscope using a Plan Achromat 4×/0.10NA objective and processed with 
ImageJ software. Scale bar 100 μm. The inset photographs of the 3D projections represent: (1) a 3D rendering 
of a confocal image of SW620 cancer cells in the reconstructed 3D-matrix tumor space. Scale bar, 100 μm; (2) 
a 3D rendering of a confocal image of the connecting-channels entering the 3D-matrix tumor space showing 
IFN-DCs moving toward cancer cells; scale bar, 100 μm. Image stacks (100 images of 1 μm Z-step size) were 
acquired using a spinning disk microscope with a 20×/0.45NA objective and processed with Imaris software; 
(3) brightfield and green fluorescence merged image (20×) of a representative connecting-channel crossed 
by one IFN-DC actively moving toward the 3D-matrix tumor space. The image was processed with ImageJ 
software. (c) Schematic representation of isometric views of microfluidic devices showing the two experimental 
configurations used: no-competition and competition settings. (d) A 3D graphic representation of a section 
of the microfluidic device showing the interconnection between immune and tumor spaces and reproducing 
the motion of migrating DCs from the immune-chamber, crossing connecting-channels, toward the tumor-
chamber, where cancer cells are targeted by infiltrated DCs.
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Preferential IFN-DC migration toward the RI tumor environment. To explore the intrinsic pro-
pensity of IFN-DCs to migrate actively toward NT as well as RI-treated cancer cells, the microfluidic platform 
was used first under the no-competition condition. NT and RI tumor spaces were reconstituted into the right 
tumor-chamber of different microfluidic platforms with PKH26-stained cancer cells, depicted as red cells. Upon 
collagen polymerization, PKH67-stained IFN-DCs, visible as green-cells, were loaded and uniformly distrib-
uted into the immune-chamber. The capability of IFN-DCs to migrate toward the chambers filled with cancer 
cells rather than matrix alone was evaluated over a period of 24 to 48 h by wide-field imaging analysis of the 
entire microfluidic device, and the total number of IFN-DCs within the micro-channels and tumor-chambers 
was quantified. We found that, while IFN-DCs did not recognize the matrix, they actively moved from the 
immune-chamber toward both tumor-chambers containing NT and RI-treated SW620 cells through the 
connecting-channels (Fig. 3a). Consistently, the number of infiltrated IFN-DCs into the 3D-tumor spaces was 
significantly higher than that infiltrated into the matrix. Notably, at both time points we found that the number of 
IFN-DCs infiltrated into the RI space was significantly higher compared to that into the NT space (Fig. 3b), and 
a remarkable fold increase of infiltrated IFN-DCs, with respect to matrix, was observed in the RI space (Fig. 3c). 
Of interest, IFN-DCs in both cases were able to migrate upward and migrate deep within the 3D-tumor space 
(Fig. 3d).
To further characterize the propensity of IFN-DCs to migrate preferentially toward drug-treated cancer cells, 
we performed experiments under the competition condition. The behaviour of IFN-DCs was evaluated over three 
time periods: 0–24 h, 24–48 h and 48–72 h. Wide-field imaging analysis showed that over the entire follow-up 
period IFN-DCs moved preferentially toward the RI-treated cancer cells, resulting in a constant higher num-
ber of infiltrating IFN-DCs into the RI tumor space as compared to that into the NT tumor space (Fig. 4a,b 
and Supplementary Fig. 2). Next, the 3D dynamics of the IFN-DC migration toward the cancer cells under the 
competition condition were captured by time-lapse recordings during a 0–72 h period (Supplementary Movies 1 
and 2). Taking advantage of an adapted unsupervised cell tracking analysis algorithm, a quantitative analysis of 
IFN-DC migration was performed by evaluating the following parameters: (i) number of migrating IFN-DCs 
accomplishing active motion across the immune-chamber, connecting-channels and tumor-chamber; (ii) 
velocity of IFN-DCs in the immune-chamber before entering the connecting-channels (Pre-channels speed); 
(iii) velocity of IFN-DCs in the tumor-chamber after passing through the connecting-channels (Post-channels 
speed); (iv) IFN-DC displacement; (v) directional persistence (DP) of IFN-DC migration; and (vi) average time 
of interaction between IFN-DCs and SW620 cells at the single-cell level. First, we defined the environments 
(background elimination step) and cells (segmentation step) in each frame of the three independent time-lapse 
experiments (Supplementary Fig. 3a,b and Supplementary Methods). By choosing the same areas of the micro-
fluidic platforms, we identified trajectories of migrating IFN-DCs with single-cell resolution and traced the single 
cell movement from the immune-chamber to the tumor-chamber over a 0–72 h period (Supplementary Table 1, 
Supplementary Fig. 4a). Software results were validated by manual ImageJ analysis (Supplementary Fig. 4b). We 
found much greater migration of IFN-DCs toward RI relative to that toward NT counterpart overtime, with 
the tendency for the RI-induced migration to reduce gradually (Fig. 5a,b). Importantly, IFN-DCs localized in 
the immune-chamber next to the RI space, where they can sense tumor-specific stimuli, moved with a higher 
constant speed as compared with those cells positioned in the corresponding area next to the NT space (0–24 h: 
5.1 μm/min vs 4.4 μm/min; 24–48 h: 5.6 μm/min vs 4.4 μm/min; 48–72 h: 5.1 μm/min vs 2.0 μm/min) (Fig. 5c and 
Supplementary Table 1). Of note, real time imaging revealed that IFN-DCs crowded the entrance and showed 
promiscuous crossing through the connecting–channels next to the RI space, in contrast the IFN-DCs moved 
toward the NT space by random walking (Supplementary Movie 3). Of interest, once in the RI space, IFN-DCs 
significantly reduced their intrinsic movement during a 0–48 h period, in contrast to the cells that migrated into 
the NT space that exhibited a slight speed reduction up to 24 h but increased the migratory speed over 48–72 h 
(0–24 h: 3.4 μm/min vs 3.0 μm/min; 24–48 h: 4.98 μm/min vs 7.7 μm/min; 48–72 h: 5.8 μm/min vs 4.9 μm/min) 
(Fig. 5d,e). These findings suggest that IFN-DCs are endowed with high capability to adapt their migration in 
response to external signals36, 37. Moreover, migrating IFN-DCs were found to move in remarkably higher num-
ber toward RI, characterized by higher DP, relative to the migration toward NT overtime (0–24 h: 571 μm vs 
480 μm, 24–48 h: 576 μm vs 474 μm, 48–72 h: 550 μm vs 441 μm) (Fig. 5f,g). Next, we characterized IFN-DC and 
cancer cell interactions and found that over 24–48 h single IFN-DCs exhibited a longer average interaction time 
with single cancer cells in RI relative to that in NT space (0–24 h: 16.1 min vs 14.9 min, 24–48 h: 11.5 min vs 
8.7 min, 48–72 h: 11.6 min vs 12 min) (Fig. 5h).
The CXCR4/CCL12 axis guides IFN-DC movement toward the RI space to capture apoptotic 
cancer cells. DC migration within the TME and toward lymph nodes is driven by a fine-tuned regulation of 
chemokine and chemokine-receptor expression38. Indeed, the IFN-DC maturation stage and functional activities 
have been reported to be regulated by responsiveness to chemokines14. In this paper, we further investigated the 
role of chemokines expressed by RI-treated SW620 cells in regulating the movement of IFN-DCs. RI-treated 
SW620 cells were found to express higher levels of CCL2, CCL4, CCL20, CCL21 as well as CXCL1, CXCL8, 
CXCL9, CXCL10, CXCL12 and CXCL14 mRNA relative to their NT counterpart (Fig. 6a). Accordingly, IFN-DCs 
exhibited elevated expression of corresponding chemokine receptor transcripts, namely CCR1, CCR2, CCR5, 
CCR6 and CCR7 as well as CXCR2, CXCR3, and CXCR4 (Fig. 6b). Next, a key role of the CXCR4/CXCL12 axis 
in the guided movement of IFN-DCs toward the RI space was defined. In fact, after SW620 cells were treated with 
RI for 48 h, they produce CXCL12 in significant amounts (Fig. 6c). Moreover, IFN-DCs exposed to conditioned 
medium (CM) from RI-treated SW620, selectively increased CXCR4 expression on the membrane compared to 
that of cells exposed to CM from NT cancer cells (Fig. 6d). Therefore, we performed migration experiments in the 
microfluidic device in the presence of the CXCR4 inhibitor AMD3100. We found that while IFN-DC migration 
toward NT was not affected by CXCR4 inhibition, the IFN-DC migration toward the RI space was significantly 
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reduced by AMD3100 already by 4 h, persisting for up to 24 h (Fig. 6e and Supplementary Fig. 5a). The inhibi-
tion of CXCR4/CXCL12-driven IFN-DC migration by AMD3100 was confirmed in a Transwell migration assay 
(Supplementary Fig. 5b). It was previously shown that DC engulfment of damaged cancer cells following their 
Figure 3. IFN-DCs migrate toward 3D tumor spaces. (a) Wide-field images of immune-tumor areas of 
microfluidic devices analysed in no-competition experiments. Brightfield images (top panels) and fluorescence 
images (bottom panels) show the preferential migration of IFN-DCs toward NT SW620 and RI SW620 spaces 
rather than an empty matrix. Images were acquired at 48 h from the start of migration using a Plan Achromat 
4×/0.10NA objective and processed with ImageJ software. Scale bar, 100 μm. One out of three independent 
experiments is shown. (b) Distribution of infiltrated IFN-DCs into NT and RI spaces versus matrix, at 24 
and 48 h. Means ± s.e.m. are shown. (N = 3 experiments; n = 6 and 5 for NT, 7 and 5 for RI, at 24 and 48 h, 
respectively. n = no. of fluorescence images analysed in each experiment). ***P ≤ 0.001, IFN-DCs migrating 
toward tumor chambers versus matrix. P = 0.5 and P = 0.047, infiltrated IFN-DCs into RI SW620 versus NT 
SW620 at 24 and 48 h, respectively (Student’s t-test). (c) Fold increase of infiltrating IFN-DCs into RI SW620 
and NT SW620 spaces, with respect to the matrix. Means ± s.e.m. are shown (*P ≤ 0.05, Student’s t-test). (d) A 
3D reconstruction of confocal image stacks (100 images of 1 μm Z-step size) of connecting-channels and tumor-
chambers acquired using a 20×/0.45NA objective. PKH67 green-stained IFN-DCs actively migrate in the three 
spatial directions into the NT (upper panel) and RI (lower panel) spaces with an increased distribution into the 
3D tumor space containing drug-treated PKH26 red-stained cancer cells. One representative image, for each 
image stack analysed, is shown. Three independent acquisitions were performed.
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scanning of the TME is pivotal for inducing antitumor immunity35. Consistently, we observed that IFN-DCs 
were able to more efficiently phagocytose RI SW620 cells compared to NT counterpart (Fig. 7a). IFN-DCs could 
migrate in three directions within the RI space, confirming the add value of our model in investigating the guided 
movement of DCs (Supplementary Movie 4). In fact, we traced the migration of a single IFN-DC toward a single 
cancer cell in the RI space and thus highlighted the events of phagocytosis (Supplementary Movie 5). In this 
process, IFN-DC moved slowly (Fig 5d,e), extended trans-cellular dendrites to establish contact with cancer 
cells (Fig. 7b), and finally phagocytosed the cancer cell (Fig. 7c). We also found some tumor Ag-loaded IFN-DCs 
migrating back into the connecting-channels (Fig. 7d), suggesting the occurrence of a second moving phase after 
phagocytosis resembling DC migration in draining lymph nodes after capture of tumor antigens39.
Figure 4. IFN-DCs preferentially migrate toward RI-treated SW620 cells. (a) Images of immune-tumor areas of 
the microfluidic devices analysed in competition experiments. Brightfield images (top panels) and fluorescence 
images (middle panels) acquired using a Plan Achromat 4×/0.10NA objective show the preferential migration 
of PKH67 green-stained IFN-DCs toward RI versus NT spaces containing PKH26 red-stained cancer cells 
at 24, 48 and 72 h observation time points (Scale bar, 100 μm). Bottom panels represent the magnification of 
boxed areas in the middle panels, acquired by 10×/0.25NA objective (Scale bar, 100 μm). One representative 
experiment out of three is shown. (b) Kinetics of migrating IFN-DCs, represented by cells counted in the 
analysed connecting-channel and tumor-chamber areas, and infiltrating IFN-DCs, represented by cells counted 
in the analysed tumor-chamber area, showing the massive recruitment of these cells by drug-treated SW620 
cells. Images acquired with 10× magnification were quantified. Means ± s.e.m. are shown (*P ≤ 0.05, **≤0.01, 
Student’s t-test) (N = 3 experiments; n = 32, 30 and 34 for NT; n = 29, 26 and 29 for RI, at 24, 48 and 72 h, 
respectively. n = no. of fluorescent images analysed).
www.nature.com/scientificreports/
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Figure 5. Analysis of IFN-DCs and RI-treated SW620 cells interaction. (a) Quantification of migrating 
IFN-DCs crossing connecting-channels towards NT or RI-treated SW620 cells by the revised unsupervised 
algorithm for cell tracking analysis of 0–72 h time-lapse recording. Images were acquired every 2 min by a Juli 
Smart microscope (4× magnification). Means ± s.d. are shown. Three independent experiments were analysed. 
(b) Migratory patterns of IFN-DCs toward NT or RI-treated SW620 cells were analysed in 0–72 h time-lapse 
experiments with cell tracking analysis. Paths of each IFN-DC crossing the connecting-channels from the 
www.nature.com/scientificreports/
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Discussion
In this paper, we exploited a novel microfluidic platform recreating interconnected 3D immune and tumor sys-
tems, to study the behaviour of IFN-DCs toward cancer cells upon treatment with two complementary antitumor 
agents, the epigenetic drug romidepsin and the immunomodulator IFN-α8. We identified the processes under-
taken by IFN-DCs for approaching dying cancer cells for Ag uptake. In particular, the following events were 
monitored and evaluated in real time: (i) IFN-DC scanning of environmental signals and adjustment of migratory 
capacity toward RI-treated cancer cells; (ii) modulation of movement parameters by IFN-DCs in performing 
guided migration in a confined space; (iii) establishment of IFN-DC-cancer cell interactions leading to Ag uptake.
DC-based immunotherapy is a promising tool for cancer treatment currently under intense investigation for 
its unique potential to initiate and direct Ag-specific T cell immune responses40. Furthermore, improved clinical 
protocols suggest that the combination of DC-based therapies with other agents may enhance the potency of 
the antitumor effects41. In this landscape, IFN-DCs are promising candidates to be combined with agents that 
promote cancer cell death and favour Ag uptake42. Here, we tested this idea and found that a high rate of CRC 
cell apoptosis following RI treatment resulted in a significant increase of phagocytosis by IFN-DCs. The choice 
to treat cells with RI in combination relies on the complementary antitumor properties of these drugs. While 
the direct and immune-mediated antitumor properties of IFN have recently renewed interest in the use of this 
cytokine in new therapeutic protocols43, HDACi have been reported to induce both cancer cell death and immu-
nomodulatory effects44. Accordingly, we found that the RI combination was able to exert direct anti-tumor effects 
and to drive DC functions against cancer cells. Importantly, although these events represent pivotal markers of 
the efficacy of immunotherapy their detection remains a true challenge45. Therefore, in the attempt to overcome 
this limitation, we employed a microfluidic approach for dissecting the intimate dialogue between IFN-DCs and 
RI-treated SW620 cells. In the past few years, the rapid technological advances have led to the development of new 
platforms for monitoring in real time the events linked to cancer development46. In order to examine the dialogue 
between cancer and immune cells, we previously employed a simplified microfluidic device. Spleen cells from 
mice knocked out for IRF-8, compartmentalized across a network of microchannels, approached cancer cells only 
by random movements, whereas single immunocompetent splenocytes accomplished drifted random migration 
leading to a highly coordinated response27, 28. Importantly, these data agreed with in vivo functional results47. 
Herein, the new design of the microfluidic platform allowed building of immune-tumor 3D spaces similar to the 
physiological environment characterized by simultaneous compartmentalization as well as by interconnections 
of the tumor and immune systems. Both the physical device architecture and the type of 3D matrix, that regulate 
the phenotype and functions of cells35, 48, were taken into consideration for reproducing spaces mimicking in vivo 
environments where DCs and cancer cells migrate and interact. First, immune-chamber dimensions recreated a 
spatial confinement, mimicking vessels and tissue interstitial areas, in which DCs, under non-specific adhesive 
conditions, were able to tune guided migration upon sensing factors released by tumor cells49. In addition, the 
geometry of the connecting-channels allowed DCs to migrate actively through very narrow constrictions to the 
same extent as when they cross endothelial barriers50. On the other hand, the microarchitecture, porosity and 
stiffness of type I collagen conferred tumor spaces with the ability to release biochemical signals from dying cells 
to guide and adapt DC movements51. Therefore, our microfluidic platform was able to recapitulate physical and 
biochemical environmental cues driving the interactions between DCs and tumor cells, closely resembling in vivo 
conditions in a time- and spatial-dependent manner. Complementary events, undetectable on 2D flat surfaces 
used in traditional assays49, such as IFN-DC migration and interaction with single cancer cell, were linked in real 
time using high-resolution time-lapse imaging. Moreover, different parameters characterizing IFN-DC behaviour 
toward NT and RI-treated cancer cells were evaluated with an automated data analysis system using a revised 
image analysis algorithm thus overcoming for the first time one of the most important challenges of microflu-
idic studies, i.e. time-consuming manual data analysis52. Specifically, IFN-DCs when sensing stimuli exclusively 
from either NT or RI-treated SW620 cells displayed a propensity to be recruited into the tumor mass but not in 
the competing matrix space. In this scenario, IFN-DC migration toward the RI space was significantly higher 
than that of cells recruited toward NT space. However, the elevated attractant potential of the molecules released 
by RI-treated dying cells toward IFN-DCs was clearly evident under competition conditions with the massive 
recruitment of these cells into RI tumor space relative to the NT counterpart. In this case, migrating IFN-DCs 
adjusted their migratory properties with respect to their functional activity49. First, in the immune-chamber 
immune-chamber in the direction of either NT or RI tumor-chambers are shown. Representative photos taken 
from three independent video recordings are shown. (c,d) Scatter plots of the migratory speed of IFN-DCs in 
the immune-chamber (pre-channel speed) and in the tumor-chambers (post-channel speed) both toward NT 
and RI-treated SW620 cells. Each data point represents the average velocity of one cell over the time periods 
of 0–24, 24–48 or 48–72 h. Horizontal bars indicate mean ± s.d. (e) Pre- and post-channel migratory speed 
of IFN-DCs toward and into the NT and RI-treated SW620 cell space over 0–72 h period. (f) Total horizontal 
path displacements of IFN-DCs. Each data point represents the average displacement of one cell over the 
time periods of 0–24, 24–48 or 48–72 h. Horizontal bars correspond to mean ± s.d. (g) IFN-DC migratory 
persistence recorded in time-lapse experiments. The DP of IFN-DCs is significantly higher toward RI than NT 
SW620 cells for up to 48 h. Each data point represents directional persistence of one cell over the time periods 
of 0–24, 24–48 or 48–72 h. Horizontal bars correspond to mean ± s.d. (h) Time of interaction between one 
IFN-DC and one SW620 cell calculated into the NT and RI tumor-chambers over the time periods of 0–24, 
24–48 or 48–72 h. The value was based on a defined circular region of interaction around each cancer cell (see 
Supplementary Information for details). Horizontal bars represent mean ± s.d. (*P ≤ 0.05, **≤0.01, ***≤0.001, 
Student’s t-test).
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Figure 6. The CXCR4/CXCL12 axis drives the migration of IFN-DCs toward RI-treated SW620 cells. 
Analysis of the expression of CC-/CXC-chemokines in SW620 cells (a) and of relative chemokine receptors 
in IFN-DCs (b) by qPCR. Expression values in the RI-treated SW620 cells and in the IFN-DCs are relative to 
the NT SW620 cells and to the GM-DCs, respectively (means ± s.e.m., *P ≤ 0.05, **≤0.01, ***≤0.001). (c) 
Immunofluorescence analysis of CXCL12 expression on both NT and RI-treated SW620. Images were collected 
with the same acquisition parameters. Scale bar, 20 µm. (d) Analysis of CXCR4 expression by flow cytometry on 
IFN-DCs after exposure to CM from 48 and 72 h NT and RI-treated SW620 cells (N = 3). (e) IFN-DC migration 
toward RI-treated SW620 cells is significantly inhibited by the CXCR4 inhibitor, AMD3100. Migration in 
the presence or absence of AMD3100 were performed in microfluidic devices, and the acquired images were 
quantified at 4 and 24 h (magnification 4×). Means ± s.e.m. are shown (*P ≤ 0.05, **≤0.01, ***≤0.001, 
Student’s t-test) (N = 3 experiments; a means of 10 images for group were analysed).
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Figure 7. IFN-DCs efficiently phagocytose RI-treated SW620 cells. (a) Fluorescence images (left panels) of 
HLA-DR-stained IFN-DCs (green) performing phagocytosis of PKH26-stained cancer cells (red) into NT or 
RI spaces, as evaluated by CLSM after 48 h from the beginning of migration in the microfluidic device under 
competition experimental conditions. The right panels show DIC (Differential Interference Contrast) images 
of the same fields. Images acquired using a UPLANSAPO 20×/0.75NA objective are shown. Zoom 3; scale 
bar, 15 μm. To avoid crosstalk between different fluorophores, sequential acquisition was performed. Data 
are representative of three independent experiments. (b) A 3D rendering of image stacks (16 slices of 0.5 μm 
Z-step size) acquired within the RI tumor space. Zoom 6; scale bar, 5 μm. One IFN-DC extending trans-
cellular dendrites toward SW620 cells is depicted in green (top panel) and one IFN-DC establishing contact 
with two different SW620 cells is depicted in green (bottom panel). (c) A 3D rendering of one IFN-DC (green) 
engulfing one SW620 cell (red) from the image stacks (16 slices of 0.5 μm Z-step size) acquired within the RI 
tumor space (left panel). Orthogonal sections of the phagocytic event depicted in the right panel are shown (left 
panels). Scale bar 5 μm. In (b and c), a 3D rendering was edited by Adobe Photoshop CC software preserving 
the original parameters of image acquisition (d) Fluorescence image showing IFN-DCs (green) crossing 
connecting-channels facing RI space upon phagocytosis of PKH26-stained SW620 cells (red) as evaluated by 
CLSM after 48 h from the beginning of migration in the microfluidic device, under competition experimental 
conditions. The right panel shows a DIC image of the same field. Images are acquired as in (a). Scale bar, 15 μm. 
Representative images of two independent experiments are shown.
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they acquired higher pre-channel speed generating crowding in entrance at connecting-channels where they 
acquired an “amoeboid-like” locomotion mode, with dendritic protrusions at the cell front and contractions at 
the cell rear, propelling the nucleus through narrow spaces thus allowing persistent cell migration53. Once in the 
RI space, IFN-DCs significantly reduced their velocity, in agreement with Ag internalization along with a con-
comitant decrease in migration upon maturation stimuli54. IFN-DCs migrating toward the RI tumor space had 
longer displacements with high DP, in contrast to the migration toward the NT space. In line with the evidence 
that chemokines may drive DC behaviour38, biochemical signals released in the RI tumor space drove IFN-DC 
migration. Enhanced transcript expression of several chemokines by RI-treated tumor cells was observed along 
with high levels of the corresponding chemokine receptors on the IFN-DCs. Such chemokines drive DC recruit-
ment into inflamed sites55. Of note, elevated CXCL12 production by RI-treated dying cells agreed with the 
increased expression of CXCR4 on IFN-DCs, a receptor known to guide mature DC motility56, thus contributing 
to IFN-DC migration toward RI tumor space. The key role of the CXCR4/CCL12 axis in driving IFN-DC chem-
otaxis toward the RI space was further confirmed by the functional inhibition with the specific CXCR4 inhibitor. 
This finding is consistent with the report showing that CXCR4 as well as the cooperation between both inducible 
CXCR3 ligands and constitutive CXCL12 regulate DC trafficking to peripheral sites57. On the contrary, the high 
CCR7 expression on IFN-DCs did not associate with the induction of CCL21 transcripts on cancer cells, suggest-
ing a minor role of the CCR7/CCL21 axis for the movement and function of IFN-DCs under these conditions.
The further analysis of DC-cancer cell interactions revealed a high competence of IFN-DCs to take up Ags 
by exploring the RI tumor space. In fact, the time of interaction between one IFN-DC and one SW620 cell was 
higher in the RI space than that in the NT space over 0–48 h period, whereas it decreased along with the aug-
mented migration velocity during the subsequent 48–72 h period. These data support the superior competence of 
IFN-DCs in patrolling drug-treated space with alternating migration phases characterized by pausing times for 
endocytosis12. IFN-DCs also established communications with cancer cells throughout trans-cellular dendrites 
when the velocity was reduced, suggesting the capability of these cells to modulate multiple functions. Finally, we 
also report that Ag-loaded IFN-DCs may make a directional choice toward the connecting-channels pointing out 
the potential of our platform for studying DC and T lymphocyte interactions, after Ag uptake58.
In summary, the microfluidic model developed in this study establishes the proof of concept for real time 
tracking of immune-tumor cell interactions and validates the efficacy of combination strategies in potentiating 
DC-based immunotherapy. Beyond this unquestionable advantage, this platform offers a valid and manageable 
alternative to studies in animals for evaluating the efficacy of novel immunotherapeutic treatments while its fur-
ther implementation may lead to the development of suitable assays for pre-clinical testing.
Methods
Cell Culture. IFN-DCs were generated using a standard protocol previously described59. Briefly, CD14+ 
monocytes were isolated from human peripheral blood mononuclear cells (PBMCs) and cultured with both 
500 U/ml GM-CSF (PeproTech, NJ) and 104 IU/ml IFN-α2b (Intron A, Merck Sharp and Dohme, Kenilworth, 
NJ) for 3 days. Then, the floating cells were collected and used for experiments. CD14+ monocytes were also cul-
tured for 3 days with GM-CSF alone, obtaining GM-DCs that were used as control in the quantitative real-time 
PCR (qPCR) experiments. For 3D microfluidic migration experiments, IFN-DCs were stained with PKH-67 
Fluorescent Cell Linker (Sigma-Aldrich), according to the manufacturer’s instructions. Low passage-number 
SW620 CRC cells were maintained in RPMI-1640 (Lonza, Verviers, Belgium) with 10% FCS (EuroClone, West 
York, UK). Cells were seeded at 3.5 × 104/cm2 and then 24 hour later were treated with or without 2 nM romidep-
sin® and 104 IU/ml IFN-α2b (I) in combination (RI) for 48 h. For 3D microfluidic migration experiments, 
SW620 cells were stained with PKH-26 Fluorescent Cell Linker (Sigma-Aldrich), according to the manufacturer’s 
instructions.
Flow cytometry. For the detection of drug-induced cell death, NT or RI-treated SW620 cells were stained 
with Annexin V-FITC and propidium iodide (PI), according to the manufacturer’s instructions. Data were 
acquired using FACS Calibur (Becton Dickinson, BD) and analysed by either WINMDI or Kaluza softwares 
(Beckman Coulter). For the immunophenotypic analysis, IFN-DCs were stained with the following monoclonal 
antibodies (mAbs): anti-CD86 (APC, clone 2331), anti-CD80 (APC-H7, clone L307.4), anti-CD123 (Brilliant 
Violet, clone 9F5) and anti-BDCA3 (PE clone 1A4), all from Becton Dickinson. Data were acquired by a Gallios 
flow cytometer (Beckman Coulter) and analysed by Kaluza software. For phagocytosis quantification, PKH-
26-labelled SW620 cells were treated with or without RI. After 48 h, dying floating cells were harvested and incu-
bated with IFN-DCs at a 1:2 ratio in conic 15 ml tissue culture tubes at 37 °C for 4 h. Then, all cells collected 
from the co-culture were stained with anti-CD11c mAb (APC, clone B-ly6, BD) followed by flow cytometry. 
The uptake of apoptotic cells by IFN-DCs was determined by calculating the percentage of double-positive cells 
(CD11c-APC+/Apo-PKH26+). All gates were set on SW620-IFN-DC co-cultures performed at 4 °C, keeping 
unchanged all the other experimental conditions. The analysis was performed with Kaluza software (Beckman 
Coulter). To analyse CXCR4 expression, IFN-DCs were cultured at 2 × 106/ml for 24 h with conditioned medium 
(CM) derived from either 48 h or 72 h cultures of NT or RI-treated SW620 cells. Stimulated or not stimu-
lated IFN-DCs were collected and stained with anti-CXCR4-PE mAb (PE, clone 12G5, eBioscience) and with 
anti-CD11c-APC (BD). Sytox dye (Thermofisher Scientific, Waltham, MA USA) was used to gather the dead 
cells. CXCR4+/CD11c+ positive cells were quantified by a Gallios flow cytometer (Beckman Coulter) and were 
analysed by Kaluza software.
Fabrication of the microfluidic devices. 3D co-culture experiments were performed in an ad 
hoc-designed cell-culture microfluidic device fabricated at the CNR-IFN facility according to already published 
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protocols60. PDMS replica and microscope glass slides were plasma oxidized (Oxford Plasma Lab 80 plus, RF 
Power: 20 W, Flux: 60 sccm, Pressure: 800 mtorr, Time: 30 s) and bonded together at 90 °C for 4 h on a hotplate. 
Selective hydrophilic activation of chamber walls by O2 plasma treatment was needed to guarantee the correct 
gel matrix positioning and the proper filling of connecting-channels before biological experiments. Microfluidic 
co-culture experiments were performed under static conditions, with passive diffusion of medium, oxygen and 
all molecular components.
Cell loading and culture in the microfluidic platform. Devices were sterilized under UV light in a lam-
inar flow hood for 15 min before loading cells. Rat-tail type I collagen (Corning, MA, USA) was prepared at 3 mg/
ml, according to the manufacturer’s instructions, and the pH was adjusted to 7 with 1 N NaOH. Collagen was 
kept for 30 min on ice before adding 25 × 104 PKH-26 labelled-NT or RI-treated SW620 cells. Then, 3.5 μl of cell/
collagen mixtures were inoculated into the tumor-chambers. In some experiments, one of the tumor-chambers 
was filled with only collagen, without tumor cells. Gels were allowed to polymerize at 37 °C for 30 min in a tissue 
culture incubator (5% CO2). Devices were filled with complete medium and stabilized at 37 °C for 30 min. Then, 
5 × 105 PKH-67 labelled-IFN-DCs were inoculated, through the loading reservoir, into the immune-chamber, 
after removing the medium. All reservoirs were then filled with 100 μl medium. Migration experiments in the 
presence of CXCR4 inhibitor were performed by adding 20 µM AMD3100 (Sigma-Aldrich) to the IFN-DCs 
before loading into the devices. For time-lapse experiments with the Juli microscope, IFN-DCs and SW620 cells 
were loaded into the devices in the absence of fluorescent staining.
Microscopy. Wide field live cell imaging was carried out with an inverted Olympus IX73 microscope 
equipped with a Lumencor Spectra X LED illumination using an Evolve Delta CCD camera (Photometrics) and 
MetaMorph V7.8.0 software (Molecular Devices). The Oko-lab incubation system was employed to control tem-
perature, humidity and CO2 during acquisition. Fluorescence and brightfield images of the entire device were 
collected at 24, 48 and 72 h both with a Plan Achromat 4×/0.10NA and 10×/0.25NA objectives (Olympus), 
and processed to quantify DC migration by automatic cell counting using ImageJ software (NIH). 3D movies 
were made by acquiring wide field image stacks (100 images of 1 μm Z-step size) every 5 min for each wave-
length using a UPLANFL long working distance 20×/0.45NA objective (Olympus). Images were processed with 
Imaris software v.8.1.2 (Bitplane). For 3D reconstruction confocal images were acquired using a X-light Nipkow 
spinning-disk head (Crest Optics). Images of 1 μm Z-step size were acquired for each wavelength (n = 100) and 
processed with Imaris software. Image stacks were edited by Adobe Photoshop CC Software (Adobe Systems) 
preserving the original parameters of image acquisition. To analyse CXCL12 expression, SW620 cells were treated 
with or without RI for 48 h. Cells were then fixed with 4% PFA for 15 min at 4 °C and stained with anti-CXCL12 
mAb (R&D, clone 79018). Images were taken with a FV1000 confocal microscope (Olympus, Tokyo, Japan) using 
a (Olympus) planapo objective 60× oil A.N. 1,42. Excitation light was obtained by a Laser Dapi 408 nm for DAPI, 
and an Argon Ion Laser (488 nm) for FITC (Alexa 488). DAPI emission was recorded from 415 to 485 nm and 
FITC emission was recorded from 495 to 550 nm.
Cell tracking analysis. IFN-DC migration toward and within the 3D tumor spaces was recorded using 
time-lapse imaging on a Juli Smart microscope placed in a CO2 incubator at 37 °C for 0–72 h. The unsupervised 
image analysis algorithm used for 2D cell tracking in a 3D environment is articulated into three main steps: (i) 
recognition of confined environment of interest in the microfluidic platform (background elimination); (ii) rec-
ognition of cells (segmentation); and (iii) construction of connections (linking)61. See Supplementary Methods 
for details. Once spaces and cells were identified in the immune-chamber, IFN-DC motion was analysed by 
evaluating the following parameters62: (i) number of migrating IFN-DCs performing active migration from the 
immune-chamber to the tumor-chamber; (ii) speed of IFN-DCs in the immune-chamber (Pre-channels speed); 
(iii) speed of IFN-DCs in the tumor-chambers (Post-channels speed); (iv) IFN-DCs displacement, which is the 
covered distance from the starting point in the immune-chamber to the ending position in the tumor-chamber; 
and (v) DP of IFN-DC migration, which is calculated by the ratio of the Euclidean distance between the starting 
and the ending position of each path and the total path length. Directional persistency values close to 1 indicate a 
strong directional path, while values close to 0 indicate dominant Brownian motion. Speed was calculated by the 
ratio of total distance travelled and the duration of migration.
Analysis of phagocytosis by Confocal Microscopy. Phagocytosis of SW620 apoptotic cells was evalu-
ated qualitatively by confocal microscopy by placing 3D microfluidic devices on 0.17 μm coverslips and by using 
immunostaining procedures adapted to previously described protocols applied to 3D cultures63. Briefly, after a 
48 h cell culture in the device, chambers and channels were washed with PBS. Then, all loading chambers were 
filled with 50 μl of 4% paraformaldehyde for cell fixation. After washing, specific labelling of the IFN-DCs was 
performed at 4 °C for 15 min, by adding 5 μl of anti-human HLA-DR-FITC Ab to the upper loading chambers. 
High-resolution images (800 × 800 pixel, 8 μs/pixel) were acquired with an IX83 FV1200 laser-scanning con-
focal microscope equipped with FluoView 4.2 software using a UPLANSAPO 20×/0.75NA objective (all from 
Olympus)64. Image stacks were processed with Imaris software for orthogonal view and 3D rendering.
Transwell migration assay. 5 × 105 IFN-DCs were resuspended in RPMI-1640 containing 0.1% bovine 
serum albumin (BSA) and seeded in the upper chambers of 8-μm porous polycarbonate membranes of 24-well 
plates (Corning, NY), in the presence or absence of 10 μM AMD3100 (Sigma-Aldrich). The lower chambers 
were filled with supernatants (CM) from NT or RI-treated SW620 cells. After a 4 h incubation at 37 °C, IFN-DCs 
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migrated through the filters into the lower compartments were collected and counted. The lower compartment of 
the control chambers contained medium alone. Each assay was performed in triplicate.
RNA extraction, cDNA synthesis and qPCR. Total RNA was extracted from the cells using the Rneasy® 
Mini kit (Qiagen), according to the manufacturer’s instructions and quantified using NanoDrop ND-1000 
(Thermo Scientific, USA). RNAs were reverse transcribed as previously described8. qPCR was performed with 
the DNA binding dye SYBR green (Power SYBR Green PCR master kit; Applied Biosystems) using an ABI 
PRISM 7900 (Applied Biosystems). qPCR were performed by using the following oligonucleotides: Homo sapi-
ens chemokine (C-C motif) receptor 4 (CCR4), NM_005508.4, For-TGTTCACTGCTGCCTTAATCCCATC, 
Rev-TGGACTGCGTGTAAGATGAGCTGG; Homo sapiens chemokine (C-C motif ) ligand 21 
(CCL21), NM_002989.3, For-TATCCTGGTTCTGGCCTTTG, Rev- CAGCCTAAGCTTGGTTCCTG; 
Homo sapiens chemokine (C-C motif ) receptor 2 (CCR2), transcript variant A, NM_001123041.2, 
For-AGAGGCATAGGGCAGTGAGA, Rev-GCAGTGAGTCATCCCAAGAG. Data were normalized to HPRT1.
qPCR using dedicated function-tested RT-qPCR assays. Applied RT-qPCR assays for selected human 
gene targets were obtained as Real-Time ready Custom Panel plate for 96 reactions (Roche Diagnostics) in a 
dried-down format. For qPCR assays an extensive list of selected human genes is reported in Supplementary 
Table 3. Each well contained specific primers and a Universal ProbeLibrary Probe. The mean of expression of 
three different housekeeping genes (HPRT1, GAPDH andPGK1) was used to normalize the data. The qPCR 
assays were run in a Roche LightCycler® 480 following the manufacturer’s instructions. qPCR assays were run in 
at least 3 independent assays.
Statistical analyses. Each experiment was repeated at least three times, yielding comparable results. 
Graphpad Prism v.5.03 (La Jolla, CA) and Microsoft Excel were used to graph the data as mean ± s.d. or s.e.m. 
and to calculate P-values using the two-tailed unpaired Student’s t-test. In all experiments, a P-value ≤ 0.05 was 
considered as statistically significant.
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